Medical Developments International Limited (MVP) AI Stock Analysis

• Market Cap: AU$48.44M
• Dividend Yield: N/A
• Average Volume (3M): 118.82K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.94
• Revenue Growth: 17.82%
• EPS Growth: N/A
• Country: AU
• Employees: 68
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): >-0.01
• Shares Outstanding: 112,658,325
• 10 Day Avg. Volume: 79,692
• 30 Day Avg. Volume: 118,816
• PEG Ratio: -6.86
• Price to Book (P/B): 1.17
• Price to Sales (P/S): 1.65
• P/FCF Ratio: -132.97
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: AU$0.85
• Price Target Upside: 54.55% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): -0.01
• Revenue Forecast (FY): AU$44.75M

• Rating: 46 Neutral
• Price Target: AU$0.45 ▼(-18.91% Downside)
• Action: Reiterated Date: 02/19/26
• Date: Action: Reiterated 02/19/26

Overall score is held back primarily by weak financial quality (very low profitability and concerning cash flow trends) and bearish technicals (below major moving averages with negative MACD). The earnings call provides some support via Pain Management growth, regulatory progress, and planned margin uplift, but valuation risk is high given the very elevated P/E and lack of dividend data.

Positive Factors

High gross margin

A 75% gross margin indicates efficient production and strong unit economics for core products like Penthrox. That margin provides enduring ability to absorb SG&A, pricing pressure or partner discounts, supporting long-term profitability upside if operating leverage improves.

Low financial leverage

Very low leverage reduces refinancing and solvency risk and gives management flexibility to fund commercialization, regulatory efforts or absorb cyclical shocks without dilutive capital raises. A strong balance sheet supports multi-quarter operational plans.

Commercial & regulatory momentum

Sustained Pain Management growth and imminent pediatric approvals expand addressable markets (ambulance/paediatric use) and support partner adoption. Durable regulatory wins plus evidence generation improve reimbursement and long-term commercial penetration.

Negative Factors

Minimal profitability

Extremely thin EBIT and net margins indicate limited ability to convert revenue into shareholder returns. Even with high gross margin, persistent low operating profitability constrains reinvestment, R&D, and resilience to cost inflation over multiple quarters.

Weak cash generation

Severely deteriorated free cash flow and historical negative operating cash flow undermine funding capacity for expansion and evidence programs. Reliance on cash reserves or external financing limits strategic optionality and increases vulnerability over the medium term.

Respiratory segment decline

A structural drop in Respiratory sales, especially in the large U.S. market, weakens product diversification and revenue stability. Prolonged softness plus tariff uncertainty and transition costs reduce scale benefits and pressure margins across reporting periods.

Medical Developments International Limited Business Overview & Revenue Model

Company Description

Medical Developments International Limited manufactures and distributes emergency medical solutions in Australia, Europe, the United States, and internationally. The company operates through Pain Management and Respiratory segments. It offers respiratory devices for sufferers of asthma and chronic obstructive pulmonary disease; Penthrox, a trauma and emergency pain relief product; and medical devices, such as CPR face shield key rings, CPR masks, finger pulse oximeters, flow meter regulators, MDI tourniquets, manually triggered ventilators, OXI port carry and hand bags, oxygen resuscitation kits, oxygen therapy masks, and resuscitators. The company was incorporated in 2003 and is headquartered in Scoresby, Australia.

How the Company Makes Money

MVP generates revenue through the sale of its medical products, particularly the Penthrox® inhalation anesthetic, which is marketed to hospitals, clinics, and emergency medical services. The company has established key partnerships with healthcare distributors and medical organizations to expand its reach and market penetration. Additionally, MVP benefits from licensing agreements and collaborations with other pharmaceutical companies, enabling it to maximize its product offerings and leverage research and development efforts. The company also focuses on ongoing product innovation and regulatory approvals to tap into new markets and increase its revenue streams.

Medical Developments International Limited Financial Statement Overview

Summary

Mixed fundamentals: modest revenue growth and strong gross margin, supported by a low-leverage balance sheet, but profitability is extremely thin and the cash flow statement is the key weakness (negative operating/free cash flow and sharply declining free cash flow growth).

Income Statement

The company has shown a modest revenue growth rate of 2.63% in the latest year, indicating some positive momentum. However, profitability remains a concern with a very low net profit margin of 0.24% and an EBIT margin of 0.36%. The gross profit margin is relatively strong at 75.35%, suggesting efficient production or service delivery. Overall, while there are signs of revenue growth, the company struggles with profitability.

Balance Sheet

The balance sheet is relatively strong with a low debt-to-equity ratio of 0.036, indicating low financial leverage and risk. The return on equity is minimal at 0.17%, reflecting challenges in generating returns for shareholders. The equity ratio is healthy, suggesting a stable financial structure. Overall, the balance sheet shows financial stability but limited profitability.

Cash Flow

The cash flow situation is concerning, with negative operating cash flow and free cash flow. The free cash flow growth rate is significantly negative at -92.85%, indicating deteriorating cash generation capabilities. The free cash flow to net income ratio is high at 11.30, suggesting that cash flow issues are not aligned with reported net income. Overall, the cash flow statement highlights significant challenges in cash generation and management.

Breakdown	TTM	Jun 2025	Jun 2024	Jun 2023	Jun 2022	Jun 2021
Income Statement
Total Revenue	40.64M	39.06M	33.15M	32.34M	21.94M	25.27M
Gross Profit	21.42M	29.43M	24.37M	-2.52M	-3.06M	16.67M
EBITDA	305.00K	1.67M	-29.45M	-4.28M	-12.86M	-11.11M
Net Income	-436.00K	94.00K	-40.99M	-5.61M	-12.41M	-12.56M
Balance Sheet
Total Assets	63.57M	66.40M	59.16M	109.49M	101.36M	100.17M
Cash, Cash Equivalents and Short-Term Investments	16.88M	17.84M	9.73M	24.66M	20.40M	36.28M
Total Debt	3.34M	1.99M	2.29M	2.56M	2.81M	3.05M
Total Liabilities	8.80M	11.29M	13.43M	28.17M	44.06M	31.87M
Stockholders Equity	54.77M	55.10M	45.73M	81.31M	57.30M	68.30M
Cash Flow
Free Cash Flow	486.00K	-486.00K	-13.95M	-24.16M	-15.94M	-15.37M
Operating Cash Flow	993.00K	-43.00K	-10.78M	-16.50M	-10.72M	-8.81M
Investing Cash Flow	-863.00K	-1.04M	-3.17M	-7.67M	-5.21M	-6.56M
Financing Cash Flow	-787.00K	8.68M	-807.00K	28.06M	142.00K	36.12M

Medical Developments International Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.55
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:MVP, the sentiment is Negative. The current price of 0.55 is above the 20-day moving average (MA) of 0.46, above the 50-day MA of 0.50, and below the 200-day MA of 0.59, indicating a bearish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 38.91 is Neutral, neither overbought nor oversold. The STOCH value of 25.93 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:MVP.

Medical Developments International Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VIT	57 Neutral	AU$27.17M	-12.06	7.64%	3.28%	0.13%	-12.90%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MVP	46 Neutral	AU$48.44M	-69.17	0.19%	―	17.82%	―
IDT	45 Neutral	AU$20.56M	-4.15	-35.58%	―	45.30%	-24.18%

Medical Developments International Limited Corporate Events

Medical Developments International Delivers Positive Cashflow as Penthrox Growth Offsets Respiratory Softness

Medical Developments International reported group revenue of $10.7 million for the December 2025 quarter and $21.6 million for the first half of FY26, with the half-year result up $1.6 million on the prior period, driven by a $2.3 million increase in Penthrox revenue and stronger volumes in Australia and Europe. The company generated $1.1 million in operating cash in Q2 and achieved positive operating cashflow of $0.3 million for the half, ending the period with $16.9 million in cash, while its respiratory segment faced softer US demand despite price increases to offset higher tariff-related costs. Operationally, Penthrox posted 26% volume growth in the Australian hospital segment, benefited from expanded PBS Prescriber Bag eligibility to nurse practitioners, and recorded 10% in‑market volume growth in Europe, where paediatric label approvals are progressing. Management signalled plans to invest further in growth initiatives and partner support to embed Penthrox as a standard of care and leverage the new paediatric indication, cautioning that these investments and distribution changes in France and Switzerland are expected to weigh on FY26 underlying EBIT but are aimed at delivering stronger long‑term financial performance.

The most recent analyst rating on (AU:MVP) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Medical Developments International Limited stock, see the AU:MVP Stock Forecast page.